| Abstract: |
Folate receptor (FR) can be used as a therapeutic target because of its expression on different epithelial cancers, such as ovarian, non- small cell lung, endometrial, and breast cancer. Assessing FR expression in tumors may help to identify patients who can benefit from FR-targeted therapeutics, such as vintafolide and farletuzumab. Different methods exist to detect FR expression. Tissue sampling has limited clinical utility, mainly because it requires an invasive procedure. 99mTc-etarfolatide, a 99mTc-labeled folate conjugate, is in latephase trials in Europe and the United States. It allows noninvasive, whole-body imaging of the FR. This review focuses on this FRimaging agent and how it may be used to direct FR-targeted therapy. © 2014 by the Society of Nuclear Medicine and Molecular Imaging, Inc. |
| Keywords: |
cancer survival; protein expression; overall survival; review; doxorubicin; cancer combination chemotherapy; drug safety; solid tumor; antineoplastic agents; clinical trials as topic; paclitaxel; cancer staging; positron emission tomography; neoplasm staging; neoplasms; disease association; carboplatin; progression free survival; ovary cancer; protein targeting; nausea; vomiting; clinical assessment; inflammation; lung cancer; drug effect; molecular imaging; docetaxel; gene expression regulation, neoplastic; isotope labeling; whole body imaging; cancer cell; positron-emission tomography; imaging; malignant neoplastic disease; contrast media; down regulation; folic acid; maximum tolerated dose; vinca alkaloids; organotechnetium compounds; tomography, emission-computed, single-photon; conjugation; spect; spect/ct; farletuzumab; folate receptor; folate receptor 1; technetium; cancer prognosis; antibodies, monoclonal, humanized; humans; human; priority journal; vintafolide; etarfolatide tc 99m; folate receptor 2; lower abdominal pain; 99mtc-etarfolatide; folate receptors, gpi-anchored
|
